.
Australian Pharmaceutical Industries (ASX:API) has swung to an interim profit after reporting a loss of $115 million the year before.
The owner of the Priceline chain generated a net profit of $21.3 million in the six months to the end of February while underlying profit grew 32 per cent to $16.2 million.
Australian Pharmaceutical has attributed the performance to earnings growth from its core business, a stronger financial position and disciplined cost control.
Looking ahead the company believes business momentum will continue for the remainder of the 2015 financial year.
A fully franked interim dividend of 2 cents per share has been declared.
